New Delhi, Aug. 1 -- Sun Pharmaceutical Industries saw its shares tumble by 5.7 percent to an intraday low of Rs.1,608.30 on the BSE on Friday, following the announcement of its first-quarter results for FY26. The stock's decline was largely triggered by a sharp 20 percent year-on-year fall in consolidated net profit to Rs.2,278 crore for the June 2025 quarter, compared to Rs.2,836 crore in the same quarter last year. On a sequential basis, however, net profit rose 6 percent from Rs.2,150 crore reported in the March 2025 quarter. Adding to the negative sentiment was the fact that several brokerages revised their target prices downward for the pharma major.

Despite the profit drop, Sun Pharma posted a healthy top-line performance. The con...